Share

August 16, 2022; 99 (7) Research Articles

Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage

A Danish Nationwide Case-Control Study

Daniel Albjerg Rudolph, Stine Munk Hald, Luis Alberto García Rodríguez, Sören Möller, Jesper Hallas, Larry B. Goldstein, David Gaist
First published May 16, 2022, DOI: https://doi.org/10.1212/WNL.0000000000200713
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
257

Share

Article Information

vol. 99 no. 7 e711-e719
DOI: 
https://doi.org/10.1212/WNL.0000000000200713
PubMed: 
35577575
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received November 17, 2021
  • Accepted in final form March 24, 2022
  • First Published May 16, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. Daniel Albjerg Rudolph,
    2. Stine Munk Hald, PhD,
    3. Luis Alberto García Rodríguez, MD,
    4. Sören Möller, PhD,
    5. Jesper Hallas, DrMedSci,
    6. Larry B. Goldstein, MD and
    7. David Gaist, PhD
  1. Daniel Albjerg Rudolph,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Stine Munk Hald, PhD,
    3. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Luis Alberto García Rodríguez, MD,
    4. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. <br>funding for travel to DDW and AHA meeting (AstraZeneca) <br>(Bayer) commercial<br>

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. <br>unrestricted research grants ( astraZeneca, Bayer) commercial<br>

    Research Support, Government Entities:

    1. <br>research grants ( EMA, Spanish drug agency)<br>

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Sören Möller, PhD,
    5. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Jesper Hallas, DrMedSci,
    6. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. <br>Member of the editorial board of Basic and Clinical <br>Pharmacology and Toxicology<br>

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. <br>I have participated in projects outside the submitted work <br>that were funded by AstraZeneca and Pfizer with money paid to <br>my employer (no personal compensation).<br>

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Larry B. Goldstein, MD and
    7. Scientific Advisory Boards:

    1. <br>Abbott- Advisor Board (PFO) - no personal income<br>

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. <br>1. Stroke, Editorial Board, 2002-<br>2. Neurology, Editorial Board, 2003 &#x0096; 2021<br>3. Cerebrovascular Diseases, Editorial Board, 2004 - (Associate <br>Editor 2012-)<br>4. Journal of Stroke and Cerebrovascular Disease (Editorial Board)<br>5. Cardiology Today, Editorial Board, 2011-<br><br>No compensation<br>

    Patents:

    1. <br>US 11,105,815 B2 August 31, 2021. University of Kentucky Research Foundation. <br>Methods for determining the presence of pathologic amylin in a subject with <br>diabetes or pre-diabetes based on detection in a skin sample.<br>

    Publishing Royalties:

    1. <br>1. Screening for Asymptomatic Carotid Stenosis, Up-to-Date, 2007-<br>2. Use and Utility of Stroke Scales and Grading Sysytems, Up-to-<br>Date, 2005-<br>

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers'Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. <br>1. NIH 5UH3NS100606-04; 9/30/2016 thru 7/31/2021; Investigator<br>2. NIH 1R01AG056628-01A1; 4/01/2018 thru 3/31/2022; Investigator<br>3. NIH 1R01NS116058-01; 4/1/2020 thru 3/31/2025; Investigator<br>4. CDC NU58DP006953-01; 6/30/2021 thru 6/29/2024; Principal Investigator<br>

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. <br>American Heart Association - Post-acute care services and outcomes among <br>elderly stroke patients<br>

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. David Gaist, PhD
    8. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. <br>D. Gaist received speaker honorarium from Bristol-Myers <br>Squibb unrelated to this work.<br>

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. <br>Novo Nordisk Foundation (grant no. NNF20OC0064637)<br>

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Research Unit for Neurology (D.A.R., S.M.H., D.G.), Odense University Hospital; University of Southern Denmark (D.A.R., S.M.H., S.M.H.), Denmark; Centro Espanõl Investigación Farmacoepidemiológica (L.A.G.R.), Madrid, Spain; Open Patient Data Explorative Network (OPEN) (S.M.), Odense University Hospital; Department of Clinical Research (S.M.), University of Southern Denmark, Odense; Department of Clinical Pharmacology, Pharmacy and Environmental Medicine (J.H.), University of Southern Denmark; and Department of Neurology and Kentucky Neuroscience Institute (L.B.G.), University of Kentucky, Lexington.
  1. Correspondence
    Dr. Gaist dgaist{at}health.sdu.dk
View Full Text

Article usage

Article usage: May 2022 to March 2023

AbstractFullPdfSource
May 20221397049Highwire
Jun 2022275010Highwire
Jul 2022255011Highwire
Aug 2022221317493Highwire
Sep 20225216831Highwire
Oct 20223652812Highwire
Nov 20223153020Highwire
Dec 20223184417Highwire
Jan 2023262215Highwire
Feb 2023294189Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Related Articles

Topics Discussed

Alert Me